Thematic area:
Decision Support & Clinical Pathway Innovation
Product:
An AI-driven clinical decision support system that delivers personalised antihypertensive treatment recommendations by analysing patient data, identifying optimal drug choices, highlighting clinical inertia, and detecting out-of-distribution cases using novel expert-in-the-loop methods.
Market:
Hypertension affects 1.3 billion people globally, with poor control rates (37%). Customers include GPs, hypertension specialists, integrated care systems, electronic health record providers, and digital health platforms. The potential market across US and EU is estimated at ~$2B annually for CDSS deployment.
Fit:
Unlike existing rule-based systems, AIBP is trained on high-quality clinical trial data and provides explainable AI outputs clinicians can trust. It directly tackles clinical inertia, one of the largest drivers of uncontrolled hypertension, and offers a powerful, scalable tool ready for commercialisation via an EI Commercialisation Fund pathway.
